Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ATLN:VX

113.000 CHF 0.900 0.80%

As of 11:43:59 ET on 03/04/2015.

Snapshot for Actelion Ltd (ATLN)

Open: 112.000 Day's Range: 111.700 - 113.500 Volume: 490,941
Previous Close: 112.100 52wk Range: 79.458 - 125.100 1-Yr Rtn: +26.54%

Stock Chart for ATLN

No chart data available.
  • ATLN:VX 113.300
  • 1D
  • 1M
  • 1Y
112.100
Interactive ATLN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ATLN

Current P/E Ratio (ttm) 21.1610
Estimated P/E(12/2015) 21.6185
Relative P/E vs. SMI 1.1399
Earnings Per Share (CHF) (ttm) 5.3400
Est. EPS (CHF) (12/2015) 5.2270
Est. PEG Ratio 1.7669
Market Cap (M CHF) 12,896.51
Shares Outstanding (M) 114.13
30 Day Average Volume 626,939
Price/Book (mrq) 6.9007
Price/Sale (ttm) 6.4240
Dividend Indicated Gross Yield 1.15%
Cash Dividend (CHF) 1.3000
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ATLN

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)

Company Profile & Key Executives for ATLN

Actelion Ltd is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for diseases with significant unmet medical needs. The Company focuses in the field of pulmonary arterial hypertension (PAH) with treatments for diseases from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

Jean-Paul ClozelCEO/Co-FounderAndre C MullerExec VP/CFO
Otto SchwarzExec VP/COONicholas FrancoExec VP/Chief Bus Dev Officer
More Company Profile & Key Executives for ATLN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil